Cambrian BioPharma Cuts 20% Stake in Sensei Biotherapeutics Ahead of Phase‑2 Data, Igniting Volatility and Investor Speculation
Discover how Cambrian BioPharma’s 20% cut in Sensei Biotherapeutics shares reflects a strategic shift, its impact on investors, and what to watch for in the upcoming Phase 2 trial.
3 minutes to read